Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SST001 in Healthy Volunteers, MSA, and PD
NCT07604116Phase 1Recruiting
- Sponsor
- SynuSight Biotech
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SST001 in multiple system atrophy (MSA) and Parkinson's disease (PD), sponsored by SynuSight Biotech. Primary endpoint: Incidence of Adverse Events at 5 days. Started Jun 2026; status: recruiting.
02
Drugs
SST001
03
Conditions
multiple system atrophy (MSA)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07604116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604116.